News | April 19, 2025
GSK’s blenrep combinations approved by UK MHRA in relapsed/refractory multiple myeloma
Blenrep combinations could redefine treatment as early as first relapse where more effective options are needed
Blenrep combinations could redefine treatment as early as first relapse where more effective options are needed
The first-of-its-kind study will evaluate potential association between GSK’s shingles vaccine and reduced dementia risk, building on growing body of evidence from observational and retrospective studies
Around 100 million people live with COPD in China, accounting for almost 25% of all COPD cases globally
Vaccine helps protect against five common disease-causing serogroups of Neisseria meningitidis (A, B, C, W and Y)
GSK secures option to multiple high-value, validated Alzheimer’s-relevant targets for drug discovery, development, and commercialization
CMG1A46 is an investigational T cell-engager with potential to deeply deplete uncontrolled B cells present in autoimmune diseases such as lupus
New Chair brings extensive experience in global pharmaceutical and biotechnology leadership, healthcare innovation, and strategic drug development
GSK and Flagship to jointly fund up to $150 million upfront
Decision on EU marketing authorisation for this population expected by September 2024
CureVac receives €400 million upfront and up to an additional €1.05 billion in development, regulatory and sales milestone payments as well as tiered royalties; all previous financial considerations from the prior collaboration agreement replaced
Subscribe To Our Newsletter & Stay Updated
